Year in review: pediatric allergy and asthma, excluding food allergy.
Division of General Pediatrics, Boston Children's Hospital, Boston, Massachusetts; Region 1 New England Pediatric Environmental Health Speciality Unit, Boston, Massachusetts; Division of Allergy and Immunology, Boston Children's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
Marissa
M
Hauptman
Division of Allergy and Immunology, Boston Children's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts. Electronic address: wanda.phipatanakul@childrens.harvard.edu.
Wanda
W
Phipatanakul
D058666:Adrenergic beta-2 Receptor Agonists / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000009:adverse effects*; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D001249:Asthma / Q000175:diagnosis / Q000191:economics / Q000453:epidemiology*; D002675:Child, Preschool; D004781:Environmental Exposure / Q000009:adverse effects*; D006801:Humans; D007223:Infant; D000069444:Omalizumab; D010575:Pesticides / Q000009:adverse effects*; D014120:Toxocariasis / Q000276:immunology*; D014481:United States
D058666:Adrenergic beta-2 Receptor Agonists; D018927:Anti-Asthmatic Agents; D000890:Anti-Infective Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D010575:Pesticides; D000069444:Omalizumab